Peripartum cardiomyopathy;Cardiomiopatia peripartum

Monaldi Archives for Chest Disease - Cardiac Series

Volumn 70, Issue 1, 2008, Pages 15-23

  Raddino, Riccardo ^a   Bonadei, Ivano ^a   Teli, Melissa ^a   Chieppa, Federica ^a   Caretta, Giorgio ^a   Robba, Debora ^a   Zanini, Gregoriana ^a   Vizzardi, Enrico ^a   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Heart failure; Left ventricular disfunction; Peripartum cardiomyopathy

Indexed keywords

CARDIOVASCULAR RISK; EARLY DIAGNOSIS; ELECTROCARDIOGRAM; HEART DISEASE; HEART FAILURE; INCIDENCE; MATERNAL AGE; MATERNAL HYPERTENSION; MULTIPARA; PERIPARTUM CARDIOMYOPATHY; PREGNANCY; PREGNANCY OUTCOME; PROGNOSIS; RACE; REVIEW; TOCOLYSIS; TWIN PREGNANCY;

EID: 44349108873     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: 10.4081/monaldi.2008.431     Document Type: Review

References (144)

1. Virchow, R. Sitzing der Berliner Geburtshilflisher Gersellskhalt, cited by Porak, C. De l'influence réciproque de la grossesse et des maladies du Coeur, thesis, Paris, 1880.
2. Ritchie C. Clinical contribution to the patho-diagnosis and treatment of certain chronic diseases of the heart. Edinburgh Med J 1850; 2: 2.
3. Porak, C. De l'influence réciproque de la grossesse et des maladies du Coeur, thesis, Paris, 1880.
4. Gouley BA, McMillan TM, bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the puerperium. Am J Med Sci 1937; 19: 185-99.
5. Hull E, Hidden E. Postpartal heart failure. South Med J 1938; 31: 265-70.
6. Veille JC. Peripartum cardiomyopathies: a review. Am J Obstet Gynecol 1984; 148: 805-18.
7. Sakakibara S, Sekiguchi M, Konno S, Kusumoto M. Idiopathic postpartum cardiomyopathy: report of a case with special reference to its ultrastructural changes in the myocardium as studies by endomyocardial biopsy. Am Heart J 1970; 80: 385-95.
8. Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic cardiomyopathy (summary of a National Heart, Lung, and Blood Institute-Workshop). Am J Cardiol 1992; 69: 1458-66.
9. Julian DG, Szekely P. Peripartum cardiomyopathy. Prog Cardiovasc Dis 1985; 27: 223-40.
10. Danbauchi SS. Echocardiographic features of peripartum cardiac failure: the Zaria syndrome. Trop Doct 2002; 32: 24-7.
11. Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation 1971; 44: 1053-61.
12. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy. National Heart Lung and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000; 283: 1183-8.
13. Hibbard JU, Lindheimer M, Lang RM. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol 1999; 94: 311-6.
14. Chapa JB, Heiberger HB, Weinert L, Decara J, Lang RM, Hibbard JU. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol 2005; 105: 1303-8.
15. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: a longitudinal echocardiographic study. Am J Obstet Gynecol 1997; 177: 1129-32.
16. Brown G, O'Leary M, Douglas I, Herkes R. Perioperative management of a case of severe peripartum cardiomyopathy. Anaesth Intensive Care 1992; 20: 80-3.
17. Forssell G, Laska J, Olofsson C, Olsson M, Mogensen L. Peripartum cardiomyopathy: three cases. J Intern Med 1994; 235: 493-6.
18. Yahagi N, Kumon K, Nakatani T. Peripartum cardiomyopathy and tachycardia followed by multiple organ failure. Anesth Analg 1994; 79: 581-2.
19. Rizeq MN, Rickenbacher PR, Fowler MB, Billingham ME. Incidence of myocarditis in peripartumcardiomyopathy. Am J Cardiol 1994; 74: 474-7.
20. Mellor DJ, Bodenham A. Infiltration anesthesia in the management of caesarian section in a patient with peripartum cardiomyopathy. Med Trop 1996; 56: 376-80.
21. Alvarez Navascues R, Marin R, Testa A, Paneda F, Alvarez Grande J. Preeclampsia and peripartum cardiomyopathy: infrequent association. Nefrologia 2001; 21: 84-7.
22. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005; 111: 2050-5.
23. Cunningham FG, Pritchard JA, Hankins GD, Anderson PL, Lucas MJ, Armstrong KF. Peripartum heart failure: Idiopathic cardiomyopathy or compounding cardiovascular events. Obstet Gynecol 1986; 67: 157-68.
24. Cetta F, michels VV. The natural history and spectrum of idiopathic dilated cardiomyopathy, including HIV and peripartum cardiomyopathy. Curr Opin Cardiol 1995; 10: 332-8.
25. Homans DC. Peripartum cardiomyopathy. N Engl J Med 1985; 312: 1432.
26. Fett JD, Carraway RD, Dowell DL, King ME, Pierre R. Peripartum cardiomyopathy in the Hospital Albert Schweitzer District of Haiti. Am J Obstet Gynecol 2002; 186: 1005-10.
27. Fett JD, Christie LG, Carraway RD, Sundstrom JB, Ansari AA. Learning from a population-based peripartum cardiomyopathy registry. Circulation 2004; 110 (III): 727.
28. Fett JD, Dowell DL, Carraway RD, Sundstrom JB, Ansari AA. One hundred cases of peripartum cardiomyopathy... and counting: what is going on? Int J Cardiol 2004; 97: 571-3.
29. Ferriere M, Sacrez A, Bouhour JB, et al. La myocardiopathie du peripartum: aspects actuels. Etude multicentrique: 11 observations. Arch Mal Coeur 1990; 83: 1563-9.
30. Cénac A, Djibo A. Postpartum cardiac failure in Sudanese-Sahelian Africa: clinical prevalence in western Niger. Am J Trop Med Hyg 1998; 58: 319-23.
31. Davidson NM, Parry EH. Peri-partum cardiac failure. Q J Med 1978; 47: 431-61.
32. Sanderson JE, Adesanya CO, Anjorin FI, Parry EH. Postpartum cardiac failure-heart failure due to volume overload? Am Heart J 1979; 97: 613.
33. Fillmore SJ, Parry EH. The evolution of peripartal heart failure in Zaria. Circulation 1977; 56: 1058.
34. Lang RM, Lampert MB, Poppas A, et al. In: Elkayam U, Gleicher N, editors. Cardiac problem in pregnancy: diagnosis and management of maternal and fetal disease. 3rd Ed. New York: Wiley-Liss; 1998. p. 87.
35. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol 1997; 176: 182-8.
36. Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 1995; 25: 118-23.
37. Heider AL, Kuller JA, Strauss RA, Wells SR. Peripartum cardiomyopathy: a review of the literature. Obstet Gynecol Surv 1999; 54: 526-531.
38. O'Connell JB, Costanzo-Nordin MR, Subramanian R, et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic, and prognostic characteristics. J Am Coll Cardiol 1986; 8: 52-6.
39. Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM. Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol 1993; 168: 493-5.
40. Lampert MB, Lang RM. Peripartum cardiomyopathy. Am Heart J 1995; 130: 860-70.
41. van Hoeven KH, Kitsis RN, Katz SD, Factor SM. Peripartum versus idiopathic dilated cardiomyopathy in young women - a comparison of clinical pathologic, and prognostic features. Int J Cardiol 1993; 40: 57-65.
42. Pierce JA, Price BO, Joyce JW. Familial occurrence of postpartal heart failure. Arch Intern Med 1963; 111: 651-5.
43. Pearl W. Familial occurrence of peripartum cardiomyopathy. Am Heart J 1995; 129: 421-2.
44. Massad LS, Reiss CK, Mutch DG, Hasket EJ. Family peripartum cardiomyopathy after molar pregnancy. Obstet Gynecol 1993; 81: 886-8.
45. Farber PA, Glasgow LA. Viral myocarditis during pregnancy: encephalomyocarditisvirus infection in mice. Am Heart J 1970; 80: 96-102.
46. Lyden DC, Huber SA. Aggravation of coxsackie virus, group B, type- 3-induced myocarditis and increase in cellular immunity to myocyte antigens in pregnant Balb/c mice and animal treated with progesterone. Cell Immunol 1984; 87: 462-72.
47. Kovithavongs T, Dossetor JB. Suppressor cells in human pregnancy. Transplant Proc 1978; 10: 911-3.
48. Thong YH, Steele RW, Vincent MM, Hensen SA, Bellanti JA. Impaired in vitro cell-mediated immunity to rubella virus during pregnancy. N Engl J Med 1973; 289: 604-6.
49. D'Cruz IA, Balani SG, Iyer LS. Infectious hepatitis and pregnancy. Obstet Gynecol 1968; 31: 449-55.
50. Sanderson JE, Olsen EG, Gatei D. Peripartum heart disease: an endomyocardial biopsy study. Br Heart J 1986; 56: 285-91.
51. Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughman KL. Peripartum myocarditis and cardiomyopathy. Circulation 1990; 81: 922-8.
52. Melvin KR, Richardson PJ, Olsen EG, Daly K, Jackson G. Peripartum cardiomyopathy due to myocarditis. N Engl J Med 1982; 307: 731-4.
53. Felker GM, Jaeger CJ, Klodas E, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 2000; 140: 785-91.
54. Chow LH, Radio SH, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 1989; 14: 915-20.
55. Hauck AJ, Kearney DL, Edwards WD. Evaluation of post-mortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for the role of sampling error. Mayo Clin Proc 1989; 64: 1235-45.
56. Ansari AA, Neckelmann N, Wang YC, Gravanis MB, Sell KW, Herskowitz A. Immunologic dialogue between cardiac myocytes, endothelial cells and mononuclear cells. Clin Immunol Immunopathol 1993; 68: 208-14.
57. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 2000; 35: 701-5.
58. Sliwa, K., Forster, O., Libhaber, E., Fett, J.D., Sundstrom, J.B., Hilfiker-Kleiner, D., Ansari, A.A. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2005 Sep 5; [Epub ahead of print].
59. Klintschar M, Schwaiger P, Mannweiler S, Regauer S, Kleiber M. Evidence of fetal microchimerism in Hashimoto's thyroiditis. J Clin Endocrinol Metab 2001; 86: 2494-8.
60. Miyashita Y, Ono M, Ono M, Ueki H, Kurasawa K. Y chromosome microchimerism in rheumatic autoimmune disease. Ann Rheum Dis 2000; 59: 655-6.
61. Johnson KL, Nelson JL, Furst DE. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis Rheum 2001; 44: 1848-54.
62. Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 2002; 23: 301-24.
63. Sundstrom JB, Fett JD, Carraway RD, Ansari AA. Is peripartum cardiomyopathy an organ-specific autoimmune disease? Autoimmun Rev 2002; 1: 73-7.
64. Warraich RS, Sliwa K, Damasceno A, et al. Impact of pregnancyrelated heart failure on humoral immunity: clinical relevance of G3- subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J 2005; 150: 263-9.
65. Warraich RS, Young JB, Sestier F, et al. Clinical and prognostic relevance of Ig-G3 reactivity in heart failure: a substudy of vasogen's immune modulation therapy in patients with chronic heart failure. J Am Coll Cardiol 2004; 43: 226A.
66. Knobel B, Melamud E, Kishon Y. Peripartum cardiomyopathy. Isr J Med Sci 1984; 20: 1061-3.
67. Liu Y, Cigola E, ChengW, et al. Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest 1995; 73: 771-87.
68. Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996; 148: 141-9.
69. Li Z, Bing OH, Long X, Robinson KG, Lakatta EG. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol 1997; 272: H2313-9.
70. Adams JW, Sakata Y, Davis MG, et al. Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A 1998; 95: 10140-5.
71. Hirota H, Chen J, Betz UA, et al. Loss of a gp 130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999; 97: 189-98.
72. Condorelli G, Morisco C, Stassi G, et al. Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 1999; 99: 3071-8.
73. Geng YJ, Ishikawa Y, Vatner DE, et al. Apoptosis of cardiac myocytes in Gs transgenic mice. Circ Res 1999; 84: 34-42.
74. Zhang D, Gaussin V, Taffet GE, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000; 6: 556-63.
75. Xing H, Zhang S, Weinheimer C, Kovacs A, Muslin AJ. 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J 2000; 19: 349-58.
76. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al. Myocardialdirected overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000; 32: 817-30.
77. Sam F, Sawyer DB, Chang DL, et al. Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. Am J Physiol 2000; 279: H422-8.
78. Palojoki E, Saraste A, Eriksson A, et al. Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. Am J Physiol 2001; 280: H2726-31.
79. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in endstage heart failure. N Engl J Med 1996; 335: 1182-9.
80. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131-41.
81. Saraste A, Pulkki K, Kallajoki M, et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest 1999; 29: 380-6.
82. Guerra S, Leri A, Wang X, et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999; 85: 856-66.
83. Haider N, Narula N, Narula J. Apoptosis in heart failure represents programmed cell survival, not death, of cardiomyocytes and likelihood of reverse remodeling. J Card Fail 2002; 9: 512-7.
84. Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 2003; 92: 139-50.
85. Dorn II GW, Brown JH. Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc Med 1999; 9: 26-34.
86. D'Angelo DD, Sakata Y, Lorenz JN, et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 1997; 94: 8121-6.
87. Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn II GW. Decompensation of pressure-overload hypertrophy in Gq-overexpressing mice. Circulation 1998; 97: 1488-95.
88. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-6.
89. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-8.
90. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
91. Jeremias I, Kupatt C, Martin-Villalba A, et al. Involvement of CD95/ Apo1/Fas in cell death after myocardial ischemia. Circulation 2000; 102: 915-20.
92. Lee P, Sata M, Lefer DJ, Factor SM,Walsh K, Kitsis RN. Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am J Physiol Heart Circ Physiol 2003; 284: H456-63.
93. Bialik S, Cryns VL, Drincic A, et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res 1999; 85: 403-14.
94. Malhotra R, Brosius III FC. Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. J Biol Chem 1999; 274: 12567-75.
95. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 1999; 99: 2934-41.
96. de Moissac D, Gurevich RM, Zheng H, Singal PK, Kirshenbaum LA. Caspase activation and mitochondrial cytochrome c release during hypoxia-mediated apoptosis of adult ventricular myocytes. J Mol Cell Cardiol 2000; 32: 53-63.
97. Kang PM, Haunstetter A, Aoki H, Usheva A, Izumo S. Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circ Res 2000; 87: 118-25.
98. Adams JW, Pagel AL, Means CK, Oksenberg D, Armstrong RC, Brown JH. Cardiomyocyte apoptosis induced by Gq signaling is mediated by permeability transition pore formation and activation of the mitochondrial death pathway. Circ Res 2000; 87: 1180-7.
99. Yussman MG, Toyokawa T, Odley A, et al. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med 2002; 8: 725-30.
100. Hayakawa Y, Chandra M, Miao W, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Gαq transgenic mice. Circulation 2003; 108: 3036-41.
101. Murphy JG. Peripartum cardiomyopathy. In: Cooper LT, editor. Myocarditis: from bench to bedside. Totowa (NJ): Humana Press; 2003. p. 589-608.
102. Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 2005; 193: 363-5.
103. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999; 283: 1335-9.
104. Cenac A, Djibo A, Sueur JM, Chaigneau C, Orfila J. Chlamydia infection and peripartum dilated cardiomyopathy in Niger. Med Trop (Mars) 2000; 60: 137-40.
105. Cenac A, Djibo A, Chaigneau C, Velmans N, Orfila J. Are anti- Chlamydia pneumoniae antibodies prognosis indicators for peripartum cardiomyopathy? J Cardiovasc Risk 2003; 10: 195-9.
106. Arnould N, Diemunsch P, Raiga J, Brettes JP. Peripartum dilated cardiomyopathies: is there a correlation with sexually transmitted diseases? Gynecol Obstet Fertil 2002; 30: 59-63.
107. Walsh JJ, Burch GE, Black WC, Ferrans VJ, Hibbs RG. Idiopathic myocardiopathy of the Puerperium (postpartal heart disease). Circulation 1965; 32: 19-31.
108. Seftel H, Susser M. Maternity and myocardial failure in African women. Br Heart J 1961; 23: 43-52.
109. Kothari SS. Aetiopathogenesis of peripartum cardiomyopathy: prolactin-selenium interaction? Int J Cardiol 1977; 60: 111.
110. Blegen SD. Post-partum congestive heart failure. Beriberi heart disease. Acta Med Scand 1965; 178: 515-24.
111. Fett JD, Ansari AA, Sundstrom JB, Combs GF. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int J Cardiol 2002; 86: 311-6.
112. Costanzo-Nordin MR, O'Connell JB. Peripartum cardiomyopathy in the 1990's etiologic and prognostic considerations and review of the literature. In: Zipes DP, Rowlands DJ, editors. Progress in cardiology. Philadelphia, PA: Lea and Febiger; 1989. p. 225-39.
113. Stamler J, Horowitz SF, Goldman ME, Matza D, Machac J. Peripartum cardiomyopathy: a role for cardiac stress determinants other than pregnancy? Mt Sinai J Med 1989; 56: 285-9.
114. Brockington IF. Postpartum hypertensive heart failure. Am J Cardiol 1971; 27: 650-8.
115. Phillips Jr JH, Burch GE. A review of cardiovascular diseases in the White and Negro races. Medicine 1960; 39: 241-88 (Baltimore).
116. Adesanya CO. Peripartum heart failure - a reappraisal of the concept. In: Akinkugbe OO, editor. Cardiovascular disease in Africa. Ikega, Nigeria: Ciba-Geigy; 1976. p. 325.
117. Brown CS, Bertolet BD. Peripartum cardiomyopathy: a comprehensive review. Am J Obstet Gynecol 1998; 178: 409-14.
118. Rahimtoola SH, Tak T. The use of digitalis in heart failure. Curr Probl Cardiol 1996; 21: 781-853.
119. Mastrobattisha JM. Angiotensin converting enzyme inhibitors in pregnancy. Semin Perinatol 1997; 21: 124-34.
120. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-14.
121. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55.
122. Lip AYH, Beevers M, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth weight. Am J Cardiol 1997; 79: 1436-8.
123. Stempel JE, O'Grady JP, Morton MJ, Johnson KA. Use of sodium nitroprusside in complications of gestational hypertension. Obstet Gynecol 1982; 60: 533-8.
124. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333: 269-75.
125. Box LC, Hanak V, Arciniegas JG. Dual coronary emboli in peripartum cardiomyopathy. Tex Heart Inst J 2004; 31: 442-4.
126. Nishi I, Ishimitsu T, Ishizu T, et al. Peripartum cardiomyopathy and biventricular thrombi. Circ J 2002; 66: 863-5.
127. Damorou FJ, Kane A, Napporn G, et al. Biventricular thrombus complicating peripartum cardiomyopathy. A case report. Dakar Med 2000; 45: 199-201.
128. Sanchez-Rubio Lezcano J, Galache Osuna JG, Marquina Barcos A, Calvo Cebollero I, Diarte de Miguel JA, Placer Peralta LJ. Peripartum cardiomyopathy with biventricular thrombi. Ann Med Intern 2004; 21: 498-500.
129. Quinn B, Doyle B, McInerney J. Postnatal pre-cordial pain. Pulmonary embolism or peripartum cardiomyopathy. Emerg Med J 2004; 21: 746-7.
130. Bennani SL, Loubaris M, Lahlou I. Postpartum cardiomyopathy revealed by acute lower limb ischemia. Ann Cardiol Angeiol 2003; 52: 382-5 (Paris).
131. Kaufman I, Bondy R, Benjamin A. Peripartum cardiomyopathy and thromboembolism; anesthetic management and clinical course of an obese, diabetic patient. Can J Anaesth 2003; 50: 161-5.
132. Pettifor JM, Benson R. Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J Pediatr 1975; 86: 459-62.
133. Aravot DJ, Banner NR, Dhalla N, et al. Heart transplantation for peripartum cardiomyopathy. Lancet 1987; 2: 1024.
134. Keogh A, Macdonald P, Spratt P, Marshman D, Larbalestier R, Kaan A. Outcome in peripartum cardiomyopathy after heart transplantation. J Heart Lung Transplant 1994; 13: 202-7.
135. Rickenbacher PR, Rizeq MN, Hunt SA, Billingham ME, Fowler MB. Long-term outcome after heart transplantation for peripartum cardiomyopathy. Am Heart J 1994; 127: 1318-23.
136. Kereiakes DJ, Parmley WW. Myocarditis and cardiomyopathy. Am Heart J 1984; 108: 1318-26.
137. Dec Jr GW, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985; 312: 885-90.
138. Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252-7.
139. Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999; 34: 177-80.
140. Sutton MS, Cole P, Plappert M, Saltzman D, Goldhaber S. Effects of subsequent pregnancy on left ventricular function in peripartum cardiomyopathy. Am Heart J 1991; 121: 1776-8.
141. Dorbala S, Brozena S, Zeb S, et al. Risk stratification of women with peripartum cardiomyopathy at initial presentation: a dobutamine stress echocardiography study. J Am Soc Echocardiogr 2005; 18: 45-8.
142. Lampert MB, Weinert L, Hibbard J, Korcarz C, Lindheimer M, Lang RM. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol 1997; 176: 189-95.
143. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001; 344: 1567-71.
144. Expert consensus document on management of cardiovascular diseases during pregnancy.The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. European Heart Journal 2003; 24: 761-781.